Zevra reports Q2 2026 results as MIPLYFFA revenue grows and EU review continues
Zevra posted $39.7 million in net revenue for the quarter, said arimoclomol prescriptions in the U.S. keep rising, and is seeking a fresh EU regulatory review while advancing its celiprolol trial.
SEC filing